This article was originally published in The Gray Sheet
Tender offer begins for the company's outstanding warrants at an exercise price of $7 and outstanding rights to acquire such warrants at $0.25 per warrant, net to seller. "Encore is making the tender offer to eliminate the potential dilutive effect that would occur if the warrants or rights to the warrants were exercised by the holders thereof on or before March 25, 2001," the firm explains. About 1.2 mil. warrants and 445,220 purchase rights are outstanding. The tender offer will remain open through Dec. 30
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.